Glofitamab monotherapy achieves durable responses in R/R DLBCL: three-year follow-up of NP30179

(5:59)

A Phase I/II trial of glofitamab monotherapy in R/R MCL

(1:45)

NP30179: Glofitamab monotherapy in R/R NHL

(50)

Update on Phase I/II study of glofitamab monotherapy in R/R MCL

(2:18)

Glofitamab for Relapsed/Refractory Large B-cell Lymphomas | Joshua Brody, MD | #ASH24

(3:26)

The emerging potential of bispecific antibodies as monotherapy \u0026 in combination for B-cell lymphoma

(5:12)

GLOBRYTE: investigating glofitamab monotherapy in patients with R/R MCL

(1:17)

Extended follow-up of glofitamab monotherapy in R/R LBCL: durability of CR and likelihood of CRS

(3:58)

Updated results of glofitamab plus polatuzumab vedotin combination therapy in DLBCL, including HGBCL

(2:54)

Mantle Cell Lymphoma: From Current Treatments to Future Innovations(Podcast)

(50:4)

Closed Caption Version - 2024 IWMF Ed Forum - Pick Your Poison Treatment Options

(48:51)

مرض هودجكن ليمفوما

(8:1econd)

Understanding Diffuse Large B-Cell Lymphoma with Jennifer Amengual, MD

(10:9)

Update on Relapsed/Refractory Diffuse Large B-Cell Lymphoma | Lymphoma Research Foundation Webinars

(1:51)

ชัวร์ก่อนแชร์ FACTSHEET : สัญญาณ มะเร็งต่อมน้ำเหลือง

(5:1econd)

ÇOCUKLARDA HODGKİN LENFOMA, ERKEN TANI YÜKSEK BAŞARI, PROF DR AHMET DEMİR

(11:45)

Understanding Bispecific Antibodies

(4:32)

สาวสปอร์ต ใจสู้! ป่วยมะเร็งต่อมน้ำเหลือง ระยะ 4 บอกกับตัวเองต้องหาย | Thairath Online

(3:33)

What are bispecific antibodies? #myeloma

(14:)

The role of TP53 \u0026 ctDNA kinetics in patients with R/R LBCL treated with glofitamab monotherapy

(5:4)

Preliminary results from NP40126: Glofitamab and R-CHOP in NHL

(1:43)

Glofitamab: a valuable agent for the treatment of patients with R/R mantle cell lymphoma

(2:)

COALITION trial: glofitamab-R-CHOP or glofitamab-pola-R-CHP in young patients with high-risk LBCL

(8:11)

Updates in bispecifics for DLBCL from ASH: glofitamab, odronextamab, epcoritamab \u0026 mosunetuzumab

(4:31)

Safety \u0026 Efficacy of Odronextamab for DLBCL After CAR-T Failure | Matthew Matasar, MD | #ASH24

(2:15)

Glofitamab step-up dosing in R/R MCL

(3:16)

A Phase I study of glofitamab plus a novel CD19 x CD28 costimulatory agonist in R/R B-NHL

(3:56)

Glofitamab and obinutuzumab in r/r MCL

(5:44)

Tycel Phillips, MD, Shares Glofitamab Data in MCL

(4:37)

Impact of TMTV on PFS following glofitamab treatment in R/R DLBCL

(2:21)